[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591598":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":28,"interventions":39,"overallOfficials":18,"centralContacts":18,"locations":47,"responsibleParty":68,"collaborators":70,"id":74,"slug":18,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":18,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":50,"whyStopped":18,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"NewAmsterdam Pharma","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Sum of Percent Change of Antioxidant Levels within HDL","The primary efficacy endpoint is the effect of obicetrapib on the sum of the percent changes in lutein, zeaxanthin, and α-tocopherol levels within HDL particles from baseline to visit 4 (week 16) compared to placebo.","16 Weeks",[14],{"measure":15,"description":16,"timeFrame":17},"Effects of Obicetrapib on Percent Changes of Antioxidant Levels in Retinal Tissue, Plasma, and HDL Particles","The secondary efficacy endpoints are the effect of obicetrapib compared to placebo on the percent changes from baseline to visit 3 (week 8) and baseline to visit 4 (week 16) for the following variables:\n\n* MPOD\n* Plasma level of α-tocopherol\n* Plasma level of lutein\n* Plasma level of zeaxanthin\n* Lutein within HDL particles\n* Zeaxanthin within HDL particles\n* α-tocopherol within HDL particles\n* Sum of the percent changes in lutein, zeaxanthin, and α-tocopherol in plasma\n* Sum of the percent changes in lutein, zeaxanthin, and α-tocopherol within HDL particles from baseline to visit 3 (week 8)\n* LDL-C\n* HDL-C\n* Non-HDL-C\n* ApoA1\n* ApoB\n* Lp(a)\n* TC\n* TG","8 and 16 weeks",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":24,"maskingDescription":18,"whoMasked":25},"DOUBLE",[26,27],"PARTICIPANT","INVESTIGATOR",[29,34],{"label":30,"type":31,"description":18,"interventionNames":32},"Obicetrapib 10mg","EXPERIMENTAL",[33],"Drug: Obicetrapib 10mg",{"label":35,"type":36,"description":18,"interventionNames":37},"Placebo","PLACEBO_COMPARATOR",[38],"Drug: Placebo",[40,44],{"type":41,"name":30,"description":42,"armGroupLabels":43,"otherNames":18},"DRUG","Active Drug",[30],{"type":41,"name":35,"description":45,"armGroupLabels":46,"otherNames":18},"Placebo Control",[35],[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Excellence Medical Research","RECRUITING","Miami Gardens","Florida","33169","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-80.2456,25.94204,{"lat":60,"lon":59},[63],{"name":64,"role":65,"phone":66,"phoneExt":18,"email":67},"Denis Ruiz","CONTACT","786-320-5229","druiz@emrclinic.com",{"type":69,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[71],{"name":72,"class":73},"MB Clinical Research and Consulting LLC","UNKNOWN","100591598",false,"NCT06982508","Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study","VERMEER","Inclusion Criteria:\n\n* Visual acuity \\> 20\u002F60 in both eyes with or without corrective lenses\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Active liver disease\n* Any clinically significant macular pathology",true,"ALL","18 Years","75 Years",{"count":86,"type":87},100,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:\n\nDo Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.\n\nParticipants will:\n\nTake Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels",[93],"Antioxidant Absorption",[95],"Healthy Volunteer","2025-10-15",{"date":98,"type":99},"2025-10-20","ACTUAL",{"date":101,"type":99},"2025-09-09",{"date":103,"type":87},"2026-12",{"name":5,"class":6},1]